Trial NCT05668936

View at ClinicalTrials.gov 
Org. Study IDs: D5671C00010
Secondary IDs: 2022-002479-12

Last trial update was posted on 2023-04-05

MeSH Interventions

Moxifloxacin Norgestimate, ethinyl estradiol drug combination

MeSH Conditions

Fatty Liver Non-alcoholic Fatty Liver Disease

Other Conditions

Non-alcoholic Steatohepatitis

Stopping Reasons

Discontinuing the development of cotadutide, a daily injectable GLP-1/glucagon co-agonist, is based on strategic pipeline considerations. The premature closure is not due to any newly observed safety signals or a change in the risk/benefit profile.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID